Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia

Summary

This is a phase 1, prospective, single-arm, open-label study. The aim of this study is to evaluate the transfusion responses of platelet increment by using Daratumumab among aplastic anemia patients with platelet transfusion refractoriness.

Timeline

Start

2023-04-17

Primary completion

2024-10-12

Completion

2024-12-01

Publications

• Gao Z, Pan H, Zhang L, Li W, Li R, Zhao J, Luo Y, Lian Y, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Li Y, Fang L, Ge M, Zheng Y, Shi J. Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia. Blood. 2025 Jun 26;145(26):3189-3193. doi: 10.1182/blood.2025029006.

Drugs

Indications